InsiderDB
Sign inStart free trial

Vertex Pharmaceuticals (VRTX)

Healthcare · Biotechnology

10 members of Congress have disclosed 28 trades in Vertex Pharmaceuticals (VRTX) since 2015: 14 buys and 14 sales. The most recent was disclosed on Nov 5, 2026. 1 trade was made by members of a committee that oversees Vertex Pharmaceuticals's industry.

Trades disclosed
28
Members trading
10
Buys / sells
14 / 14
Reported value
$70K–$525K

Keep following the company.

Subscribers get new congressional filings and notable insider purchases for companies they follow. Coverage varies by company.

Follow VRTX

What else is happening at VRTX

All research →

Company filings and public records connected to this stock, ordered by when they became public or were first observed.

  1. VRTXFinancial report·SEC EDGAR

    VRTX: 10-Q financial filing

    Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.

    Public: Nov 3, 2026, 4:04 PM ESTEvent / period: Sep 30, 2026Original source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  2. VRTXCompany announcement·SEC EDGAR

    VRTX: Financial results

    Filed 8-K for an event or period dated 2026-11-02. Financial results.

    Public: Nov 2, 2026, 4:05 PM ESTEvent / period: Nov 2, 2026Original source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  3. VRTXLobbying report·Lobbying disclosures

    VRTX: third_quarter 2026 lobbying report

    Access to innovative non-opioid medicines. Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.

    Public: Oct 20, 2026, 10:46 PM EDTOriginal source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  4. VRTXLobbying report·Lobbying disclosures

    VRTX: third_quarter 2026 lobbying report

    Issues related to pain management, including S.475/H.R. 1227 - Alternatives to PAIN Act. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to tariff and trade policy.

    Public: Oct 20, 2026, 5:54 PM EDTOriginal source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  5. VRTXLobbying report·Lobbying disclosures

    VRTX: third_quarter 2026 lobbying report

    International trade issues impacting pharmaceutical industry.

    Public: Oct 20, 2026, 4:36 PM EDTOriginal source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

Committee overlaps

Trades by members of a committee that oversees Vertex Pharmaceuticals's industry. An overlap is a fact about the trade, not evidence of wrongdoing.

Who traded VRTX

All trades

From periodic transaction reports filed under the STOCK Act. Amounts are the ranges members report, and trades can be disclosed up to 45 days after they happen. Nothing here is investment advice.